PsyBio Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020
Period Ending	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-1.9	-4.89	-11.02	-6.44
Depreciation & Amortization	0.11	0.15	-	-
Loss (Gain) From Sale of Investments	-0	0.16	0.06	-
Stock-Based Compensation	0.31	0.51	2.13	3.85
Other Operating Activities	-0.91	0.02	1.21	0.62
Change in Accounts Payable	0.78	0.84	0.49	0.57
Change in Other Net Operating Assets	0.03	-0.23	0.18	0.53
Operating Cash Flow	-1.59	-3.44	-6.95	-0.86
Cash Acquisitions	-	-	0.18	-
Investment in Securities	0.86	3.52	-3.74	-
Investing Cash Flow	0.86	3.52	-3.56	-
Long-Term Debt Repaid	-	-0.12	-	-
Net Debt Issued (Repaid)	-0.04	-0.12	-	-
Issuance of Common Stock	0.69	0.16	11.28	1.16
Repurchase of Common Stock	-0.01	-0.09	-	-
Other Financing Activities	0.32	-	-0.91	-
Financing Cash Flow	0.96	-0.05	10.37	1.16
Foreign Exchange Rate Adjustments	0	0	0	-
Net Cash Flow	-0.02	0.03	-0.15	0.29
Levered Free Cash Flow	-0.34	-1.42	-3.68	-
Unlevered Free Cash Flow	-0.33	-1.4	-3.68	-
Change in Net Working Capital	-0.89	-0.74	0.16	-

Updated Aug 30, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.